Synthetic Biologics and Intrexon have commenced development of a monoclonal antibody (mAb) therapy, SYN-005, to treat pertussis, commonly known as whooping cough. To manage the rising number of pertussis cases, Synthetic Biologics intends ...
Tags: Synthetic Biologics, monoclonal antibody therapy, whooping cough
GlaxoSmithKline (GSK) has announced FDA approval of raxibacumab anti-toxin as a combination therapy along with antibacterial drugs for the treatment of inhalational anthrax in both adult and pediatric patients with limited treatment ...
The European Union has granted CE mark to Abacus Diagnostica's molecular diagnostic assay, designed for detecting toxin-producing Clostridium difficile. The GenomEra C. difficile assay, which is designed for use with the company's ...
TNI BioTech (TNIB) has entered into a memorandum of agreement (MOU) with GB Oncology and Imaging Group to equip and operate oncology and infectious diseases clinics in Malabo, Equatorial Guinea. Under the agreement, TNIB will deliver ...
Tags: Infectious Diseases Clinic, health care clinic, company cooperation
SRI International has received a new grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a topical microbicide gel for drug delivery. The topical microbicide gel, which will be based on a patented ...
During the month of October, Lancôme, world's largest luxury beauty brand, donates $7 from the in-store or online sale of every bottle of select Génifique products to St. Jude, one of the world's premier centers for the ...
Tags: Lancôme, luxury beauty brand, St.Jude Children's Research Hospital
Laser system scans and manipulates bacterium 10 Oct 2012 Optical trap grabs and analyses even smallest unicellular organisms Freiburg:home to new optical trap.Researchers at the Department of Microsystems Engineering(IMTEK)of the ...
Fraunhofer Center for Molecular Biotechnology (FhCMB) has received a contract from the US National Institute of Allergy and Infectious Diseases to develop vaccine technologies for advancing the next generation of anthrax vaccines. ...
Tags: FhCMB, anthrax vaccines, NIH
Janssen-Cilag International has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval to use the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as ...
Tags: investigational drug bedaquiline, multi-drug resistant tuberculosis
Collaborative Drug Discovery (CDD) and SRI International have won a second grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, for the joint development of an ...
Tags: Collaborative Drug Discovery, CDD, tuberculosis, TB
Janssen Research & Development company has submitted bedaquiline (TMC207) new drug application (NDA) to the US Food and Drug Administration (FDA) for approval. Bedaquiline,an investigational drug administered orally,is used as part of ...
Tags: FDA, new drug application, investigational drug, pulmonary
CLC bio has implemented specialized antibody engineering and selection software for Crucell, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that integrates with CLC bio's bioinformatics platform. The specialized module ...
Tags: CLC bio, bioinformatics platform
Evotec and Haplogen have signed a drug discovery partnership targeting viral infectious diseases. The drugs resulting from the partnership are expected to target a human protein that is vital for the spread of pathogenic viral ...
Tags: the human protein, targeting viral infectious diseases, Haplogen, Evotec
PDS Biotechnology has entered into a licensing agreement with Merck KgaA, Germany, for use of PDS Biotechnology's Versamune nanotechnology platform. Under the terms of the agreement, Merck will obtain the rights to use the technology ...
Tags: Versamune nanotechnology platform, company cooperation
The research collaboration will leverage Mucosis' Mimopath platform technology in Crucell's program for developing undisclosed novel vaccines to combat infectious diseases. Mucosis CEO Thomas Johnston said Mimopath platform combined ...
Tags: License Option Agreement, biotechnology, novel vaccines